The Promise And Peril Of AI In Clinical Trials

Artificial intelligence (AI) is revolutionizing clinical research, but it also brings forth potential risks that need to be managed and mitigated. Currently, the majority of organizations are either exploring or planning to implement AI and machine learning (ML) in their clinical data workflows. AI has already made an impact on the drug pipeline, with numerous ongoing trials for molecules discovered by AI-native biotechs and their pharmaceutical partners. However, concerns regarding bias, inconsistency, and safety in AI systems must be addressed.

Despite these concerns, there is a genuine movement and trust in adopting AI models due to their incredible utility. AI is expected to play a significant role in the future of the pharmaceutical industry. To enhance the drug development process, it is crucial to incorporate patient and community input alongside technology and data, particularly in AI-enabled clinical trial planning, design, and execution.